Arrowhead Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ARWR Nasdaq 2836 arrowheadpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026 - May 27th, 2026 5:00 am
Arrowhead Data On Plozasiran Expands Cardiometabolic Opportunity And Investor Focus - May 26th, 2026 1:16 pm
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress - May 26th, 2026 8:00 am
Bernstein Lifts PT on Arrowhead Pharmaceuticals (ARWR) Following Biotech’s Solid Start to 2026 - May 26th, 2026 6:43 am
Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum - May 20th, 2026 8:07 am
Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA - May 20th, 2026 7:00 am
Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near - May 14th, 2026 3:09 am
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After Its Recent Share Price Momentum - May 12th, 2026 5:18 pm
ARWR: Multiple Important Clinical Readouts in 2H26 - May 12th, 2026 4:14 am
Arrowhead (ARWR) Q2 2026 Earnings Transcript - May 8th, 2026 8:17 am
Arrowhead Pharmaceuticals Q2 Earnings Call Highlights - May 7th, 2026 4:39 pm
Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results - May 7th, 2026 2:01 pm
Arrowhead and Madrigal sign global licence for MASH RNAi therapy - May 6th, 2026 4:29 am
Should Madrigal’s ARO-PNPLA3 License Deal Reshape the MASH Strategy for Madrigal Pharmaceuticals (MDGL) Investors? - May 5th, 2026 9:15 pm
Madrigal outlays $1bn for Arrowhead’s siRNA MASH asset - May 5th, 2026 9:53 am
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals - May 5th, 2026 6:00 am
Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline - May 5th, 2026 6:00 am
Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events - May 4th, 2026 5:30 am
The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Australian Approval Of REDEMPLO For FCS - May 4th, 2026 3:09 am
Arrowhead (ARWR) Rated Buy on Metabolic Pipeline Potential - May 2nd, 2026 11:51 am